Seeking Alpha

Simcere Pharmaceutical (SCR -0.3%) slips after reporting a Q4 loss of $0.06 per ADS, versus flat...

Simcere Pharmaceutical (SCR -0.3%) slips after reporting a Q4 loss of $0.06 per ADS, versus flat consensus estimates, primarily due to a non-cash impairment charge of as the result of a write-down of intangible assets, goodwill, and assets held for sale associated with the acquisition of Jiangsu Quanyi Biological Technology. Gross margin also fell to 81.1%, compared to 82.3%. Read more on earnings here: Earnings Call Transcript.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|